GILD Financials: Gilead Sciences, Inc AI Analysis



Financials

GILD Financial

Gilead Sciences, Inc

$130.06

-0.45%

$-0.59

As of today:May 21, 12:41:45 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$130.66

Open

$130.52

Day's Range

$129.42 - $131.28

52 week range

$96.18 - $157.29

Volume

1.3M

Avg.Volume

6.8M

Dividend yield

3.55%

EPS (TTM)

7.35

Market Cap

$161.4B

What is GILD?

Gilead Sciences, Inc. is a biopharmaceutical company that engages in the research, development, and commercialization of medicines addressing unmet medical needs. Headquartered in Foster City, California, the company currently employs 17,600 full-time employees. It advances medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. Gilead focuses on discovering, developing, and delivering therapies for unmet needs in virology, oncology, and other therapeutic areas. Its marketed product portfolio includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Product candidates in development include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. The company is also advancing the HB-400 and HB-500 programs—therapies intended to deliver functional cures for hepatitis B virus and human immunodeficiency virus-1. Additionally, Gilead has a cancer program named TREX1. The company operates in more than 35 countries worldwide.

Features

Markets

News

Breakdown	TTM	03/31/2026	12/31/2025	09/30/2025	06/30/2025	03/31/2025
Revenue	29,736	6,960	7,925	7,769	7,082	6,667
Revenue Growth (YoY)	3%	4%	5%	3%	2%	0%
Cost of Revenue	6,139	1,445	1,624	1,569	1,501	1,540
Gross Profit	23,597	5,515	6,301	6,200	5,581	5,127
Selling, General & Admin	5,913	1,426	1,777	1,352	1,358	1,222
Research & Development	5,745	1,358	1,568	1,334	1,485	1,341
Operating Expenses	11,657	2,783	3,345	2,686	2,843	2,563
Other Non Operating Income (Expenses)	79	-3	1	87	-6	4
Pretax Income	10,728	2,580	2,078	3,641	2,429	1,649
Income Tax Expense	1,511	559	-105	589	468	334
Net Income	9,216	2,021	2,183	3,052	1,960	1,315
Net Income Growth	55%	54%	22%	144%	21%	-132%
Shares Outstanding (Diluted)	1,254	1,254	1,252	1,254	1,255	1,259
Shares Change (YoY)	0%	0%	-2%	0%	0%	1%
EPS (Diluted)	7.34	1.61	1.74	2.43	1.56	1.04
EPS Growth	56%	55%	25%	143%	21%	-131%
Free Cash Flow	10,018	2,427	2,763	4,108	720	1,653
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	79.35%	79.23%	79.5%	79.8%	78.8%	76.9%
Operating Margin	40.15%	39.25%	37.29%	45.23%	38.66%	38.45%
Profit Margin	30.99%	29.03%	27.54%	39.28%	27.67%	19.72%
Free Cash Flow Margin	33.68%	34.87%	34.86%	52.87%	10.16%	24.79%
EBITDA	16,080	3,421	5,716	--	3,429	3,260
EBITDA Margin	54.07%	49.15%	72.12%	--	48.41%	48.89%
D&A For EBITDA	4,140	689	2,760	--	691	696
EBIT	11,940	2,732	2,956	3,514	2,738	2,564
EBIT Margin	40.15%	39.25%	37.29%	45.23%	38.66%	38.45%
Effective Tax Rate	14.08%	21.66%	-5.05%	16.17%	19.26%	20.25%

Breakdown

TTM

03/31/2026

12/31/2025

09/30/2025

06/30/2025

03/31/2025

Revenue

29,736

6,960

7,925

7,769

7,082

6,667

Revenue Growth (YoY)

Cost of Revenue

6,139

1,445

1,624

1,569

1,501

1,540

Gross Profit

23,597

5,515

6,301

6,200

5,581

5,127

Selling, General & Admin

5,913

1,426

1,777

1,352

1,358

1,222

Research & Development

5,745

1,358

1,568

1,334

1,485

1,341

Operating Expenses

11,657

2,783

3,345

2,686

2,843

2,563

Other Non Operating Income (Expenses)

-3

-6

Pretax Income

10,728

2,580

2,078

3,641

2,429

1,649

Income Tax Expense

1,511

559

-105

589

468

334

Net Income

9,216

2,021

2,183

3,052

1,960

1,315

Net Income Growth

55%

54%

22%

144%

21%

-132%

Shares Outstanding (Diluted)

1,254

1,252

1,254

1,255

1,259

Shares Change (YoY)

-2%

EPS (Diluted)

7.34

1.61

1.74

2.43

1.56

1.04

EPS Growth

56%

55%

25%

143%

21%

-131%

Free Cash Flow

10,018

2,427

2,763

4,108

720

1,653

Free Cash Flow Per Share

Gross Margin

79.35%

79.23%

79.5%

79.8%

78.8%

76.9%

Operating Margin

40.15%

39.25%

37.29%

45.23%

38.66%

38.45%

Profit Margin

30.99%

29.03%

27.54%

39.28%

27.67%

19.72%

Free Cash Flow Margin

33.68%

34.87%

34.86%

52.87%

10.16%

24.79%

EBITDA

16,080

3,421

5,716

3,429

3,260

EBITDA Margin

54.07%

49.15%

72.12%

48.41%

48.89%

D&A For EBITDA

4,140

689

2,760

691

696

EBIT

11,940

2,732

2,956

3,514

2,738

2,564

EBIT Margin

40.15%

39.25%

37.29%

45.23%

38.66%

38.45%

Effective Tax Rate

14.08%

21.66%

-5.05%

16.17%

19.26%

20.25%

Follow-Up Questions

What are Gilead Sciences, Inc's key financial statements?



According to the latest financial statement (Form-10K), Gilead Sciences, Inc has a total asset of $0, Net loss of $0

What are the key financial ratios for GILD?



Gilead Sciences, Inc's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Gilead Sciences, Inc's revenue broken down by segment or geography?



Currently Gilead Sciences, Inc data is not available.

Is Gilead Sciences, Inc profitable?



no, according to the latest financial statements, Gilead Sciences, Inc has a net loss of $0

Does Gilead Sciences, Inc have any liabilities?



no, Gilead Sciences, Inc has liability of 0

How many outstanding shares for Gilead Sciences, Inc?



Gilead Sciences, Inc has a total outstanding shares of 0

Gilead Sciences, Inc (GILD) Financial

GILD Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is GILD?

Gilead Sciences, Inc (GILD) Financial

GILD Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is GILD?

GILD Income

Follow-Up Questions

What are Gilead Sciences, Inc's key financial statements?

What are the key financial ratios for GILD?

How is Gilead Sciences, Inc's revenue broken down by segment or geography?

Is Gilead Sciences, Inc profitable?

Does Gilead Sciences, Inc have any liabilities?

How many outstanding shares for Gilead Sciences, Inc?